Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.29
-0.15-4.36%
At close: -
$3.48
0.195.78%
After Hours: 9:23 AM EDT
Comments
Loading...
Cardiff Oncology Analyst Ratings and Price Targets | NASDAQ:CRDF | Benzinga
Cardiff Oncology Inc has a consensus price target of $10.8 based on the ratings of 5 analysts. The high is $17 issued by HC Wainwright & Co. on February 28, 2025. The low is $6 issued by Baird on August 29, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on February 28, 2025, December 13, 2024, and November 8, 2024, respectively. With an average price target of $13.33 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 283.14% upside for Cardiff Oncology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
HC Wainwright & Co.
Craig-Hallum
Baird
1calculated from analyst ratings
Analyst Ratings for Cardiff Oncology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/28/2025 | Buy Now | 388.51% | HC Wainwright & Co. | Robert Burns42% | $13 → $17 | Maintains | Buy | Get Alert |
| 12/13/2024 | Buy Now | 187.36% | Piper Sandler | Joseph Catanzaro41% | $7 → $10 | Maintains | Overweight | Get Alert |
| 11/08/2024 | Buy Now | 273.56% | HC Wainwright & Co. | Raghuram Selvaraju42% | $14 → $13 | Maintains | Buy | Get Alert |
| 09/06/2024 | Buy Now | 129.89% | Craig-Hallum | Albert Lowe27% | → $8 | Initiates | → Buy | Get Alert |
| 05/06/2024 | Buy Now | 302.3% | HC Wainwright & Co. | Raghuram Selvaraju42% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 302.3% | HC Wainwright & Co. | Raghuram Selvaraju42% | $12 → $14 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 101.15% | Piper Sandler | Joseph Catanzaro41% | $5 → $7 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 244.83% | HC Wainwright & Co. | Raghuram Selvaraju42% | $13 → $12 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 273.56% | HC Wainwright & Co. | Raghuram Selvaraju42% | $14 → $13 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 302.3% | HC Wainwright & Co. | Raghuram Selvaraju42% | $15 → $14 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | 331.03% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $15 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 331.03% | HC Wainwright & Co. | Raghuram Selvaraju42% | $14 → $15 | Maintains | Buy | Get Alert |
| 09/16/2022 | Buy Now | 302.3% | HC Wainwright & Co. | Raghuram Selvaraju42% | $22 → $14 | Maintains | Buy | Get Alert |
| 09/13/2022 | Buy Now | 43.68% | Piper Sandler | Joseph Catanzaro41% | $7 → $5 | Maintains | Overweight | Get Alert |
| 08/29/2022 | Buy Now | 72.41% | Baird | Joel Beatty69% | $9 → $6 | Maintains | Outperform | Get Alert |
| 05/09/2022 | Buy Now | 532.18% | HC Wainwright & Co. | Raghuram Selvaraju42% | $25 → $22 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cardiff Oncology (CRDF) stock?
The latest price target for Cardiff Oncology (NASDAQ:CRDF) was reported by HC Wainwright & Co. on February 28, 2025. The analyst firm set a price target for $17.00 expecting CRDF to rise to within 12 months (a possible 388.51% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
The latest analyst rating for Cardiff Oncology (NASDAQ:CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
When was the last upgrade for Cardiff Oncology (CRDF)?
There is no last upgrade for Cardiff Oncology
When was the last downgrade for Cardiff Oncology (CRDF)?
There is no last downgrade for Cardiff Oncology.
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $13.00 to $17.00. The current price Cardiff Oncology (CRDF) is trading at is $3.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.